Literature DB >> 16372316

Systemic oxybutynin decreases afferent activity of the pelvic nerve of the rat: new insights into the working mechanism of antimuscarinics.

Kevin De Laet1, Stefan De Wachter, Jean-Jacques Wyndaele.   

Abstract

AIMS: In a rat model, intravesical oxybutynin was recently shown to suppress pelvic afferent nerves. This study evaluates if a similar effect exists after systemic administration of oxybutynin.
METHODS: Twenty-four single afferent bladder nerves were identified in 15 rats. Based on their conduction velocities they were grouped as C or Adelta fibers. Bladder filling parameters and afferent nerve spike rate were simultaneously recorded 30 min before administration of saline (nine fibers) or oxybutynin (15 fibers, 1 mg/kg), and again 30, 60, 90, 120, and 150 min after systemic saline or drug administration.
RESULTS: No change in C or Adelta afferent spike rate was observed after saline injection (P > 0.90). In the study group, a decrease in afferent activity was noted after systemic administration of oxybutynin for C fibers, which were statistically significant 90 (P < 0.004) and 120 min (P < 0.028) after drug delivery. After 150 min, the spike rate was still lower compared to the baseline filling, without reaching the level of significance (P > 0.09). For the Adelta fibers the decrease in afferent spike rate was already significant at 30 min (P < 0.005) and remained significant during all subsequent fillings (P < 0.012). To avoid a possible confounding influence of the bladder compliance, which increased significantly after injection of oxybutynin (P < 0.011), afferent activity during bladder filling was recalculated. Normalized afferent sensitivity of C and Adelta fibers decreased significantly after injection of oxybutynin. This means that the decrease in afferent spike rate is not the result of an increased compliance.
CONCLUSIONS: The findings of this study strongly suggest that oxybutynin directly or indirectly influences bladder sensory nerves, inhibiting the afferent part of the micturition reflex. (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16372316     DOI: 10.1002/nau.20208

Source DB:  PubMed          Journal:  Neurourol Urodyn        ISSN: 0733-2467            Impact factor:   2.696


  13 in total

Review 1.  [Oral anticholinergics in overactive bladder].

Authors:  H Madersbacher
Journal:  Urologe A       Date:  2006-07       Impact factor: 0.639

Review 2.  Urothelial effects of oral agents for overactive bladder.

Authors:  Karl-Erik Andersson; Claudius Fullhase; Roberto Soler
Journal:  Curr Urol Rep       Date:  2008-11       Impact factor: 3.092

Review 3.  Urothelial signaling.

Authors:  Lori Birder; Karl-Erik Andersson
Journal:  Physiol Rev       Date:  2013-04       Impact factor: 37.312

4.  Drugs and future candidates.

Authors:  Karl-Erik Andersson
Journal:  Can Urol Assoc J       Date:  2011-10       Impact factor: 1.862

Review 5.  Best practice in the management of storage symptoms in male lower urinary tract symptoms: a review of the evidence base.

Authors:  Mauro Gacci; Arcangelo Sebastianelli; Pietro Spatafora; Giovanni Corona; Sergio Serni; Dirk De Ridder; Stavros Gravas; Paul Abrams
Journal:  Ther Adv Urol       Date:  2017-12-07

Review 6.  Urodynamics in the evaluation of overactive bladder.

Authors:  Eric S Rovner; Colin M Goudelocke
Journal:  Curr Urol Rep       Date:  2010-09       Impact factor: 3.092

7.  Solifenacin objectively decreases urinary sensation in women with overactive bladder syndrome.

Authors:  Lior Lowenstein; Kimberly Kenton; Elizabeth R Mueller; Linda Brubaker; Edmond Sabo; Ramón A Durazo-Arivzu; Mary P Fitzgerald
Journal:  Int Urol Nephrol       Date:  2011-10-13       Impact factor: 2.370

Review 8.  The efficacy of mirabegron in the treatment of urgency and the potential utility of combination therapy.

Authors:  Karl-Erik Andersson; Nurul Choudhury; Jean-Nicolas Cornu; Moses Huang; Cees Korstanje; Emad Siddiqui; Philip Van Kerrebroeck
Journal:  Ther Adv Urol       Date:  2018-07-06

Review 9.  From urothelial signalling to experiencing a sensation related to the urinary bladder.

Authors:  L Birder; J-J Wyndaele
Journal:  Acta Physiol (Oxf)       Date:  2012-10-30       Impact factor: 6.311

10.  Patient perspectives in the management of overactive bladder, focus on transdermal oxybutynin.

Authors:  Tondalaya Gamble; Peter Sand
Journal:  Patient Prefer Adherence       Date:  2008-02-02       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.